Celldex Therapeutics, Inc vs. Intellia Therapeutics, Inc
Celldex Therapeutics, Inc and Intellia Therapeutics, Inc are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| CLDX | NTLA | |
|---|---|---|
| Market Cap | $3.02 billion | $1.72 billion |
| Revenue (TTM) | — | $59.51 million |
| Net Income (TTM) | — | $-399,975,000 |
CLDX leads on 1 of 1 size & scale factors.
Valuation
| CLDX | NTLA | |
|---|---|---|
| Price / Book | — | 2.36 |
| Price / Sales | — | 28.87 |
CLDX and NTLA split the valuation factors evenly.
Profitability
| CLDX | NTLA | |
|---|---|---|
| Net Margin | — | -672.16% |
| Return on Equity | — | -54.96% |
CLDX and NTLA split the profitability factors evenly.
Risk & Sentiment
| CLDX | NTLA | |
|---|---|---|
| Short Interest | 9.28% | 2.43% |
NTLA leads on 1 of 1 risk & sentiment factors.
Dig deeper: CLDX overview, CLDX financials, NTLA overview, NTLA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.